Literature DB >> 21309481

Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells.

H Zhang1, D Zhang, X Luan, G Xie, X Pan.   

Abstract

Signal transducers and activators of transcription (STAT) are important in the development of laryngeal carcinomas and are potential novel molecular targets for therapy to improve survival of patients with this cancer. This study was designed to investigate the influence of the janus activated kinase (JAK)/STAT inhibitor AG490 on proliferation and apoptosis of Hep-2 human laryngeal cancer cells and whether there was any inhibition by AG490 of the JAK/STAT3 signalling pathway. AG490 inhibited cell proliferation in dose- and time-dependent manners and induced apoptosis in Hep-2 cells, with the number of apoptotic cells increasing with time. AG490 inhibited G1 to S cell cycle transition and induced G1 cell cycle arrest as well as significantly down-regulating STAT3, phosphorylated STAT3 and survivin in Hep-2 cells. This study showed that AG490 significantly inhibited proliferation and induced apoptosis of laryngeal carcinoma cells through down-regulation of STAT3 and survivin, suggesting a potential target for laryngeal carcinoma treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21309481     DOI: 10.1177/147323001003800512

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  8 in total

1.  Identification of laryngeal cancer prognostic biomarkers using an inflammatory gene-related, competitive endogenous RNA network.

Authors:  Qun He; Linli Tian; Hao Jiang; Jiarui Zhang; Qiang Li; Yanan Sun; Jiannan Zhao; Huijun Li; Ming Liu
Journal:  Oncotarget       Date:  2017-02-07

2.  Down-regulation of SOX18 inhibits laryngeal carcinoma cell proliferation, migration, and invasion through JAK2/STAT3 signaling.

Authors:  Yice Xu; Qingyuan Zhang; Jie Zhou; Zhaolong Li; Junyu Guo; Weina Wang; Wei Wang
Journal:  Biosci Rep       Date:  2019-07-05       Impact factor: 3.840

3.  Esculetin Inhibits Proliferation, Invasion, and Migration of Laryngeal Cancer In Vitro and In Vivo by Inhibiting Janus Kinas (JAK)-Signal Transducer and Activator of Transcription-3 (STAT3) Activation.

Authors:  Geng Zhang; Yi Xu; Hui-Fang Zhou
Journal:  Med Sci Monit       Date:  2019-10-20

4.  Sporoderm-Removed Ganoderma lucidum Spore Powder May Suppress the Proliferation, Migration, and Invasion of Esophageal Squamous Cell Carcinoma Cells Through PI3K/AKT/mTOR and Erk Pathway.

Authors:  Guiping Liu; Tao Zeng
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

Review 5.  Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.

Authors:  Hyun-Seuk Moon; Maria Dalamaga; Sang-Yong Kim; Stergios A Polyzos; Ole-Petter Hamnvik; Faidon Magkos; Jason Paruthi; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2013-03-08       Impact factor: 19.871

6.  Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.

Authors:  Venhar Gurbuz; Ece Konac; Nuray Varol; Akin Yilmaz; Serhat Gurocak; Sevda Menevse; Sinan Sozen
Journal:  Oncol Lett       Date:  2014-01-14       Impact factor: 2.967

7.  Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways.

Authors:  Zhi Lan Guo; Jing Zhe Li; Yan Yan Ma; Dan Qian; Ju Ying Zhong; Meng Meng Jin; Peng Huang; Lu Yang Che; Bing Pan; Yi Wang; Zhen Xiao Sun; Chang Zhen Liu
Journal:  BMC Cell Biol       Date:  2018-12-29       Impact factor: 4.241

8.  Determination of SIRT1 rs12778366, FGFR2 rs2981582, STAT3 rs744166, and RAGE rs1800625 Single Gene Polymorphisms in Patients with Laryngeal Squamous Cell Carcinoma.

Authors:  Virgilijus Uloza; Toma Tamauskaite; Alvita Vilkeviciute; Agne Pasvenskaite; Vykintas Liutkevicius; Rasa Liutkeviciene
Journal:  Dis Markers       Date:  2019-11-12       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.